Source: CureToday articles
The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.
Recent Content
- Immune Therapy Expands Melanoma Treatment to More Patients
- The Importance of Personalized Treatment Approaches for Urologic Cancers
- Nurse’s Big Personality Makes Cancer Treatment More Bearable.
- Constraint-Induced Cognitive Therapy Found to Improve Multiple Long COVID Symptoms
- Givinostat Wins U.S. FDA Fast Track Designation for Patients With PV
- Expert: Understanding OTC Allergy Medications and Symptom Management
- One Dose of the HPV Vaccine Is over 97% Effective at Preventing HPV Infection
- First Patient With Advanced Lung Cancer Dosed With Peluntamig Combo
- Psilocybin at the Crossroads: Regulatory Barriers and the Pharmacist’s Role in Palliative Innovation
- Study Demonstrates Semaglutide Improves Liver Histologic Results in Patients With MASH